---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-150830"
form_type: "8-K"
ticker: "CGEM"
cik: "0001789972"
company_name: "Cullinan Therapeutics, Inc."
filed_at: "2022-05-16T23:59:59+00:00"
generated_at: "2026-06-25T15:19:50.539583+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Cullinan Oncology Q1 net loss $12.9M; Taiho deal adds $275M, extends cash runway through 2026

## Summary
- Cash and investments $410M at March 31, 2022; $685M including $275M Taiho upfront; runway extended to 2026.
- Net loss $12.9M vs $34.2M Q4 2021; R&D expense $24.5M, G&A $8.1M.
- CLN-081 co-development deal with Taiho: $275M upfront, up to $130M milestones, 50/50 US profit share.
- CLN-081 granted Breakthrough Therapy Designation; 41% confirmed ORR at 100mg BID; ASCO oral June 2022.
- IND filings for CLN-617 and CLN-978 on track for H1 2023; CLN-049 and CLN-619 Phase 1 dosing ongoing.

## SEC filing metadata
- accession: 0001193125-22-150830
- form_type: 8-K
- ticker: CGEM
- cik: 0001789972
- company_name: Cullinan Therapeutics, Inc.
- filed_at: 2022-05-16T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1789972/000119312522150830/0001193125-22-150830-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1789972/000119312522150830/d696900d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-150830
- JSON: https://secwatch.observer/filing/0001193125-22-150830.json
- Plain text: https://secwatch.observer/filing/0001193125-22-150830.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.